Direkt zum Inhalt

Inwald, E. C. ; Ortmann, O. ; Zeman, F. ; Koller, M. ; Hofstädter, F. ; Gerstenhauer, M. ; Klinkhammer-Schalke, M.

Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

Inwald, E. C., Ortmann, O., Zeman, F., Koller, M., Hofstädter, F., Gerstenhauer, M. and Klinkhammer-Schalke, M. (2014) Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry. BioMed Research International 2014, pp. 1-10.

Date of publication of this fulltext: 19 Dec 2024 08:16
Article



Involved Institutions


Details

Item typeArticle
Journal or Publication TitleBioMed Research International
Publisher:HINDAWI PUBLISHING CORPORATION
Place of Publication:NEW YORK
Volume:2014
Page Range:pp. 1-10
Date2014
InstitutionsMedicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde)
Identification Number
ValueType
10.1155/2014/137304DOI
KeywordsADHERENT ADJUVANT TREATMENT; PHASE-II TRIAL; MULTICENTER COHORT; CLINICAL-ONCOLOGY/COLLEGE; MONOCLONAL-ANTIBODY; AMERICAN-SOCIETY; FOLLOW-UP; TRASTUZUMAB; CHEMOTHERAPY; RECOMMENDATIONS;
Dewey Decimal Classification600 Technology > 610 Medical sciences Medicine
StatusPublished
RefereedYes, this version has been refereed
Created at the University of RegensburgYes
Item ID61879

Export bibliographical data

Owner only: item control page

nach oben